1. Controlling leukocyte trafficking in IBD.
Veny M, Fernández-Clotet A, Panés J. Pharmacol Res. 2020;159:105050. doi:10.1016/j.phrs.2020.105050

2. Quality of care standards in inflammatory bowel diseases: a European Crohn’s and Colitis Organisation (ECCO) position paper.
Fiorino G, Lytras T, Younge L, et al. [published online ahead of print, 2020 Feb 7]. J Crohns Colitis. 2020;jjaa023. doi:10.1093/ecco-jcc/jjaa023

3. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP, Chaparro M. J Crohns Colitis. 2020;14(5):694-709. doi:10.1093/ecco-jcc/jjz195

4. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment.
Adamina M, Bonovas S, Raine T, et al. J Crohns Colitis. 2020;14(2):155-168. doi:10.1093/ecco-jcc/jjz187

5. Improving Quality of Care in Inflammatory Bowel Disease Through Patients’ Eyes: IQCARO Project.
Calvet X, Saldaña R, Carpio D, et al. Inflamm Bowel Dis. 2020;26(5):782-791. doi:10.1093/ibd/izz126

6. JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease.
Macaluso FS, Rodríguez-Lago I. Curr Drug Metab. 2020;21(4):247-255. doi:10.2174/1389200221666200310111409

7. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment.
Torres J, Bonovas S, Doherty G, et al. J Crohns Colitis. 2020;14(1):4-22. doi:10.1093/ecco-jcc/jjz180

8. COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020).
Marín-Jiménez I, Zabana Y, Rodríguez-Lago I, et al. Gastroenterol Hepatol. 2020;43(7):408-413. doi:10.1016/j.gastrohep.2020.05.003

9. A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective.
Louis E, Ramos-Goñi JM, Cuervo J, et al. Patient. 2020;13(3):317-325. doi:10.1007/s40271-019-00407-5

10. Practical guidelines on endoscopic treatment for Crohn’s disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group.
Shen B, Kochhar G, Navaneethan U, et al. Lancet Gastroenterol Hepatol. 2020;5(4):393-405. doi:10.1016/S2468-1253(19)30366-8

11. Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations.
Casellas F, Ginard Vicens D, García-López S, et al. [published online ahead of print, 2020 Aug 14]. Eur J Gastroenterol Hepatol. 2020;10.1097/MEG.0000000000001885. doi:10.1097/MEG.0000000000001885

12. Treatment dilemmas at different stages of the disease.
Barreiro-de Acosta M, Bastón-Rey I, Calviño-Suárez C, Enrique Domínguez-Muñoz J. United European Gastroenterol J. 2020;8(3):256-262. doi:10.1177/2050640619900571

13. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
Kim H, Alten R, Avedano L, et al. [published correction appears in Drugs. 2020 Jul;80(10):1039-1040]. Drugs. 2020;80(2):99-113. doi:10.1007/s40265-020-01256-5

14. Are there reliable predictive factors of nonresponse to aminosalicylates in patients with ulcerative colitis?
Gisbert JP, Chaparro M. United European Gastroenterol J. 2019;7(8):997-998. doi:10.1177/2050640619861891